Faculty Opinions Recommendation of Lymphatic Vessels Interact Dynamically with the Hair Follicle Stem Cell Niche During Skin Regeneration In Vivo

    Jiro Kishimoto
    Image of study
    TLDR Lymphatic vessels and hair follicles interact and may influence hair growth.
    In 2021, Peña-Jimenez D and colleagues reported on the dynamic interaction between lymphatic vessels (LVs) and hair follicles (HFs) in mice. They found that LVs are polarized along the anterior permanent region of the HF and that this LV-HF association is maintained by the formation of a HF stem cell niche. The study also revealed different gene expression between two hair cycle stages (late telogen and anagen onset), suggesting that LVs influence the normal hair regeneration cycle. Although the study was conducted on mice, the authors suggested that the findings could be significant for studying human HF physiology and clinical applications due to the conservation of the LV network in the skin and lymphatic system between rodents and humans.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 6 results

      community New and Interesting HairLoss Studies/Papers/Reviews

      in Treatment  42 upvotes 4 years ago
      Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

      community 4 months on 2.5 mg OM, no improvement

      in Minoxidil  6 upvotes 1 year ago
      After 4 months on oral minoxidil with no significant hair regrowth, a user is frustrated and considering alternative treatments since they can't take finasteride due to side effects. Suggestions include natural DHT blockers, lifestyle changes, and other hair care tips.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  39 upvotes 1 year ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

    Related Research

    1 / 1 results